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ABSTRACT 
Mucus is a dynamic barrier which covers and protects the underlying mucosal epithelial 
membrane against bacteria and foreign particles. This protection mechanism extends to include 
therapeutic macromolecules and nanoparticles (NPs) through trapping of these particles. 
Mucus is not only a physical barrier that limiting particles movements based on their sizes but 
it selectively binds with particles through both hydrophilic and lipophilic interactions. 
Therefore, nano-carriers for mucosal delivery should be designed to eliminate entrapment by 
the mucus barrier. For this reason, different strategies have been approached for both solid 
nano-carriers and liquid core nano-carriers to synthesise muco-diffusive nano-carrier. Among 
these nano-strategies, Self-Emulsifying Drug Delivery System (SEDDS) was recognised as 
very promising nano-carrier for mucus delivery. The system was introduced to enhance the 
dissolution and bioavailability of orally administered insoluble drugs. SEDDS has shown high 
stability against intestinal enzymatic activity and more importantly, relatively rapid permeation 
characteristics across mucus barrier. The high diffusivity of SEDDS has been tested using 
various in vitro measurement techniques including both bulk and individual measurement of 
droplets diffusion within mucus. The selection and processing of an optimum in vitro technique 
is of great importance to avoid misinterpretation of the diffusivity of SEDDS through mucus 
barrier. In conclusion, SEDDS is a system with high capacity to diffuse through intestinal 
mucus even though this system has not been studied to the same extent as solid nano-carriers.   
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1. General Introduction 
Mucus is a dynamic barrier that protects the underneath mucosal epithelial membrane in the 
body. Mucus barrier has a varied thickness depending on the site of the body which it can be 
as thin as 0.578 µm  in the eye [1] to a thick barrier of 150 µm in the colon [2]. Any therapeutic 
agent administered through mucosal routes needs to permeate through mucus to reach the 
underlying epithelial membrane and be further absorbed by the systemic circulation [3]. 
Although permeation of small molecules through mucus barrier is not restricted process [4], 
macromolecules like peptides and proteins are highly susceptible to being trapped by mucus or 
degraded by protease enzymes in the mucus layer [5]. The incorporation of such therapeutic 
agents into a proper nano-system can improve their diffusion through the mucus barrier and 
provide protection against enzymes [6].  
However, the permeation of these nano-carriers can be highly constrained due to either size 
exclusion by mucin network or interaction with mucus components where these interactions 
can be either of electrostatic or lipophilic nature [7,8]. Therefore, an ideal nano-carrier for 
mucosal delivery should avoid mucus entrapment [9] and shield the loaded drugs from 
intestinal enzymes [10]. The candidate nano-system should escape mucus clearance through 
fast diffusion across mucus barrier [11] and stay close to the epithelial surface to ensure a 
maximum absorption of the released drug close to the epithelial surface [12]. The key 
requirement for nano-carriers is to be permeable across mucus barrier. This aim was achieved 
using the following strategies: (i) synthesising of particles with hydrophilic inert surface to 
eliminate the possibility of interaction with mucus components, or (ii) loading of particles with 
mucolytic agents to reversibly disrupt the mucus barrier [13,14].  
Self-Emulsifying Drug Delivery System (SEDDS) is very auspicious nano-systems. This 
systems can easily be formed by simply mixing ingredients [15] which makes it highly suitable 
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for industrial purposes since large batches can be prepared without any sophisticated 
technology. SEDDS was introduced to overcome the solubility issue of lipophilic agents which 
in turn affects their oral bioavailability [16]. Moreover, this system was found to have longer 
persistence in the GIT and improved drug cellular uptake [17]. More importantly, recent studies 
have shown that SEDDS is a very efficient nano-carrier for oral delivery of hydrophilic 
peptides and proteins through protecting of these peptides from GIT environment and enhance 
their penetration through intestinal mucus barrier [18]. 
The purpose of this review is to describe the mucus barrier in general and to explicitly elucidate 
the mechanisms by which intestinal mucus barrier traps droplets of SEDDS. The reason to 
focus on the intestinal mucus barrier is due to the fact that SEDDS and most of the solid nano-
carriers are mainly delivered orally. We will compare the main nano-strategies to improve the 
permeation of solid core nanoparticles (NP) and liquid core nano-carriers across the intestinal 
mucus barrier. SEDDS will be reviewed extensively in relation to how the liquid core nano-
carrier can improve the mucus delivery of both lipophilic and hydrophilic agents. In this 
review, SEDDS will be used to define all types of self-emulsifying systems including the 
Micro-Emulsifying and Nano-Emulsifying systems   (SMEDDS/SNEDDS) since SEDDS has 
been used to describe these systems more recently [19]. Lastly, technologies to quantify 
SEDDS permeation across mucus will be outlined.  
2. Barrier Properties of Mucus  
2.1 Compositions of Intestinal Mucus and Mucin Structure  
Generally, regardless of site in the body, mucus is mainly composed of macromolecular 
glycoprotein units called mucin, high water content (90-95%) and other ingredients including 
DNA, lipids, electrolytes, bacteria and sloughed epithelial membrane [20,21]. The ratios of 
these ingredients vary depending on the site of the body. Measurement of the percentages of 
components in dried intestinal mucus revealed the presence of 5% mucin and 6% DNA [22]. 
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The same study showed that lipids and proteins are existed in high percentages (40%) within 
the intestinal dried mucus.  The high lipid content in the intestinal mucus is associated with 
breakdown of food rich with lipids while the high DNA percentage is related to the regularly 
shedding of intestinal epithelial membrane [23]. At average concentration of 30 mg/ml, mucin 
units connect to each other via hydrogen bonding, hydrophobic and electrostatic interactions 
to form a network having the properties of hydrogel system [23]. This mucin network swells 
upon absorption of water leading to formation of gel like structure of mucus [24,25]. 
Structurally, mucin is a macromolecular glycoprotein having large molecular weight (M.wt) 
(2000-10000 kDa) [26,27]. Purified mucin units are curvilinear fibres with an average diameter 
of about 5–7 nm  and a length of approximately 200 to 4000 nm [28,29]. Each macromolecular 
unit consists of 3 to 4 subunits with average M.wt of 4 x 105 Da [30]. Mucin subunits are large 
polypeptide chains that composed of glycosylated and non-glycosylated domains in a 
sequential manner where polypeptide chains in the glycosylated domain are densely covered 
with polysaccharide glycosylated side chains while non-glycosylated domains are cysteine-
rich domains that connecting  glycosylated regions by intramolecular disulphide bonds [31]. 
Functionally, the main roles of mucus are lubrication, hydration and protection of the 
underlying epithelial membrane against mechanical stress, foreign particles and pathogens 
[32,33]. Hence, mucus in the GIT is relatively thick with high mechanical strength to protect 
against the high content of pathogens and microorganisms as well as the highly acidic 
environment [34,35]. Physically, intestinal mucus can be described as a semipermeable 
membrane from which only particles as small as nutrients and drug molecules can permeate 
[36]. If these molecules are stable against pH and enzymes in the GIT environment, they can 
be absorbed through the intestinal epithelial layer. On the other hand, crossing the 
gastrointestinal mucus barrier is a challenge to enzymatically labile therapeutic 
macromolecules like peptides due to their propensity to hydrolyse and degrade in the GIT. 
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Hence, these peptides must be protected from the GIT environment by encapsulation within a 
proper nanocarrier [13]. However, as was described above, these particles get trapped by the 
intestinal mucus [37]. The trapping of these NPs is due to the unique physiochemical properties 
of mucus [38–40].  
2.2 Physicochemical Properties of Mucus  
Mucin units, as the main building entities of the mucus, are mainly responsible for the 
physicochemical properties of mucus, specifically, through the unique chemical nature of the 
glycosylated protein domains and the non-glycosylated cysteine-rich protein regions. Thus, the 
negatively charged nature of mucus is associated with the glycosylated protein domains which 
are rich with sialic acid and also contains to less extent galactose sulphate ester units [41]. With 
a pKa of approximately 2, Sialic acid units are totally charged at the physiological pH which 
results in the negatively charged nature of mucus in the intestine [42]. Besides that, the 
negatively charged nature of mucin is also obtained from its polypeptide backbone chain which 
conatins both aspartic acid and glutamic acid units [43]. On the other hand, the lipophilicity of 
mucus is mainly due to the high lipophilicity of the cysteine-rich circular domains of mucin 
(Figure 1) [44]. Furthermore, the polysaccharide side chain exerts some lipophilicity within the 
mucin through the methyl groups of the polysaccharide fucose units [45].  
Accordingly, the viscoelastic nature of mucus is directly related to the gel network of mucin 
which is formed through the disulphide bridges between mucin units [46]. The mechanical 
strength of this network is directly related to the extent of  interdigitating among glycosidic 
side chains which results in a stable three-dimensional mucin network with higher mechanical 
strength [47]. The lengths of these polysaccharide side chains are responsible for the 
interdigitating process where long polysaccharide chains are responsible for forming of hard 
gel mucus while small chains are associated with forming of mucus with weak viscous 
properties [48].  
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Fig.1. Mucin macromolecular conformation.  
Mucus has different mechanical and viscoelastic properties depending on where it is situated 
in the body. In the intestine where SEDDS and most of the solid and liquid core nano-carriers 
are delivered, there are two layers of mucus with different mechanical properties [49]. These 
are: the outer layer which is a loose structure that colonised with bacteria and inner layer which 
is a dense structure that is resistant to bacterial penetration  [50,51]. The loose mucus layer is 
characterised by a shear thinning rheological behaviour which has protective lubricating effect 
against bacteria and foreign particles  [52].  
2.3 How Physicochemical Properties Affect Barrier Properties of Intestinal Mucus against NPs 
Permeation 
 
The mechanism of trapping of orally given NPs and SEDDS depends on the physicochemical 
properties of mucus and includes two processes which occur simultaneously upon the passage 
of any foreign particles. Firstly, a gluey cage of mucus (Figure 2) is formed in which 
droplets/particles are efficiently trapped by mucus components through formation of numerous 
dynamic interactions of both lipophilic and hydrophilic nature [53]. Concurrently, the passage 
of particles/droplets under peristalsis movement exerts a shear thinning effect on the mucus 
layers which leads to sliding of these layers over each other and dropping of the viscosity [54]. 
As a result, a lubricated pathway of mucus layers with low viscosity is formed through which 
droplets/particles trapped in cages are moved.   As a result, macromolecular NPs/SEDDS in 
extracellular mucus are highly trapped as compared with particles at molecular level. Ideally, 
NPs/SEDDS  should permeate quickly through the loose intestinal mucus layer to avoid being 
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rapidly eliminated with the loose mucus clearance [10]. This allows enough time for the 
complete release of drug molecules adjacent to the epithelial membrane.   
 
Fig. 2. Trapping mechanism of intestinal mucus towards orally administered particles/droplets. 
 
3. Strategies in Nanotechnologies to Improve Mucus Permeation  
Nanotechnologies that have been explored for mucus permeation include solid nano-carriers 
and lipid based liquid nano-carriers like liposomes and SMEDDS. Solid NPs provide the 
opportunity for surface modifications to form inert or electrostatically neutral surfaces which 
can minimize their mucus interaction and consequentially allow permeation [55,56]. On the 
other hand, lipid based liquid nano-carriers can offer enhanced leverage towards mucus 
permeation by virtue of their flexible structure and ability to squeeze through the mucus 
networks [18]. Both nano-systems offer the ability for tuning of their particle sizes and the 
capacity to be loaded with various hydrophilic and lipophilic agents [57,58]. 
3.1 Solid Nano-Carrier 
A variety of strategies were examined to improve the mucus diffusivity of solid nano-carriers. 
These strategies have been classified into three fundamental categories: (i) formation of 
slippery surface nano-carriers by modulating of particles’ surface properties to enhance their 
diffusion through the mucus barrier (ii) formation of mucolytic nano-carriers to reversibly 
disrupt the mucus barrier (iii) a combination of slippery surface and mucolytic particles where 
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a mucolytic agent is loaded onto a surface modified nanocarrier to allow synergistic 
permeation. 
3.1.1 Slippery Surface NPs  
This strategy was adopted from certain viruses with inert neutral surfaces like poliovirus and 
human papilloma which were found to diffuse freely across  mucus barrier [59]. These mucus 
diffusive  viruses are covered with densely-charged but neutral capsid shell (without lipophilic 
membrane) [60] to avoid any electrostatic/H-Bond interactions with mucus [61]. Similarly, 
inert surface NP is a NP in which the neutral hydrophilic surface totally covers the internal 
lipophilic core [62] to avoid lipophilic interaction and an inert neutral surface to avoid any 
electrostatic/H-bond interaction with the mucus components [63] .  
Two strategies have been utilised to form slippery NPs with inert surface properties. The first 
is through coating of NP with a neutral hydrophilic polymer such as PEG polymer. The mucus 
permeability of densely PEGylated NPs has been deeply explored in term of the effect of degree 
of surface PEGylation on their diffusion  [55]. Studies on different mucus sources revealed that 
densely PEGylated NPs have high diffusion across vaginal mucus [64], cystic fibrosis (CF) 
mucus [65] and respiratory mucus [66]. Accordingly, other hydrophilic surfactants were 
examined for formation of inert surface NPs and their permeation through mucus [67]. For 
example, hydrophilic pluronic surfactant with low M.wt was used to coat PLGA NPs where 
coated particles showed high diffusion across chronic rhinosinusitis mucus that is retarded by 
only 20 times in comparison with its free diffusion in water [68]. The second strategy used to 
form inert surface NP involves mixing of polymers with opposite charges as such alginate (-
ve) and chitosan (+ve) where electrostatic interaction leads to precipitation of polyelectrolyte 
(PEC) polymer in nanoscale range  to form PEC NPs with a densely neutrally charged surface 
[69]. For example, self-assembled polyelectrolyte NPs of poly(acrylic acid) (PAA) and 
poly(allylamine) (PAM) show a diffusion coefficient of 2.5 times higher than the positively 
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charged NPs and around two times the diffusion of (-ve) PAA NPs [70]. Similarly, 
condensation of the negatively charged DNA with the positively charged 
dimethyldioctadecylammonium bromide (DDAB) on the surface of PLGA NP particles show 
a tenfold higher diffusion coefficient to that of the same size lipophilic NP [71]. Other coating 
mixtures such as dextran–protamine (near neutrality charge) was reported to increase mucus 
permeability of solid lipid NPs [72].  
3.1.2 Mucolytic NPs 
Mucolytic agents can vastly enhance the NPs diffusion across mucosal barrier through 
reversible destruction of the mucin network [73] where loading into and releasing of these 
agents from NPs reduce the resistance of mucus towards the permeation of NPs [73]. Three 
types of mucolytic agents have been utilised to improve NPs permeation across mucus [74]. 
Firstly are disulfide breaking agents which cleave disulfide bonds within mucin network. These 
agents are exemplified by N-acetyl cysteine (NAC), dithiotreitol and glutathione. Secondly are 
proteolytic agents which break mucin’s peptide bonds (bromelain, trypsin and papain). Thirdly 
are DNA hydrolysing agents which split DNA tangles that entangled within the mucin network 
[75,76].    
Muller el al. showed that polyacrylic acid (PAA) NP loaded with the papain proteolytic agent 
has three times faster diffusion through intestinal porcine mucus than the PAA NPs containing 
no papain [77]. In vivo examination of PAA-papain NPs in the Sprague Dawley rats showed 
an extended residence time in the jejunum which indicates high permeability through the mucus 
loose layer [78]. On the other hand, disulfide breaking agent represented by NAC significantly 
increased the permeation of 3.2 µm polystyrene micro-particles through rat intestinal mucus 
[79].  
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Moreover, a mucolytic agent can be used as adjuvant factor in combination with modified 
surface NPs to boost the mucus diffusion of inert surface NPs where this combination can have 
a synergistic effect. For instance, prior treatment of CF mucus with disulfide breaking agent 
(NAC) showed a synergistic effect on the diffusion coefficient of surface-modified particles 
with PEG where the diffusion of particles with combined strategies approached its free 
diffusion in water. Conversely each of the strategies applied separately had limited 
improvement on mucus permeation [80]. 
3.2 Mucus Permeation of Lipid Based Nano-Carrier with Liquid Core  
Liposomes and SEDDS are the main lipid based nano-carriers with liquid core being 
investigated for oral delivery of peptides [81,82]. While SEDDS has been studied in more 
depth, liposomes have been reported in a few publications for their ability to permeate through 
the mucus barrier. This drug delivery system consists of an aqueous core covered by multiple 
or singular bilayers made of biocompatible lipids of natural or synthetic origin. This unique 
form of Liposomes provides an opportunity to load both water soluble and lipophilic agents in 
their aqueous cores or lipid bilayer respectively [83].  
Modification of liposomes’ surfaces was utilised to enhance oral delivery of proteins with the 
intent to have high mucus permeation [84]. Specifically, slippery liposome coated with an inert 
PEG polymer was the main strategy to enable muco-diffusive liposomes. For example, work 
by Sanders et al. where lipoplex densely covered with inert PEG (5000) was used for gene 
transfection [85]. This study showed that the PEGylated lipoplexes had better gene transfection 
efficiency by virtue of minimal interaction with CF mucus as compared to cationic lipoplexes. 
In a similar study for oral delivery of cyclosporine, liposome was coated with inert an 
hydrophilic polymer (Pluronic F-127) in comparison with chitosan coat [86]. The study showed 
that liposome coated Pluronic F-127 expressed higher diffusion through intestinal mucus, 
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higher stability in the GIT environment and double the bioavailability of the liposomes coated 
with chitosan.  
Another study showed that PEGylated liposomes permeated 10% slower through vaginal 
mucus compared to its movement in water with the diffusion being proportional to PEG density 
on the surface of liposomes [87]. The PEGylated Liposomal system was also found to be 
effective in the delivery of oligonucleotides based antibiotics against H. Pylori at the surface 
of gastric epithelia. PEGylated liposomes improved the mucus permeation of these 
oligonucleotides agents which on their own were found to be highly trapped due to the 
macromolecular nature of these antibiotics [88].  
4. Mucus Permeation of Self-Emulsifying Drug Delivery system  
4.1 SEDDS for Delivery of Hydrophilic/Lipophilic Agents  
This system is an isotropic mixture of oils, aqueous phase and emulsifiers in which oil phase 
and emulsifiers can be simultaneously transformed into nano-droplets upon contacting any 
aqueous solvents such as intestinal fluids [89]. Oil and surfactants combinations can be diluted 
in the excess GIT fluid to form these systems [90]. This unique formation mechanism makes 
these systems highly suitable for oral delivery. A further convincing reason for suitability of 
SEDDS for oral nano-delivery is that the preparation of these systems do not require sluggish 
size reduction techniques associated with other nanosystems [91]. For oral administration of 
SEDDS, the combination of oils and surfactants are generally administered via a gastro-
resistant capsular system so that the acidic barrier of the stomach can be avoided. The capsule 
consequently gets into intimate contact with intestinal fluid once reaching the intestine; SEDDS 
is readily formed with nano sized droplets. The emulsification process is spontaneous due to 
the usage of more than one surfactant and/or co-surfactant for the formation of SEDDS which 
can minimise the interfacial tension between the two phases when they come in contact [92,93]. 
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This combination usually comprises short or medium chain triglyceride oils along with 
surfactant/co-surfactant mixtures consisting of the derivatives of glycerides and non-ionic 
surfactants with high HLB value [94,95].   
SEDDS is a very efficient system to deliver lipophilic drugs from Class 2 and 4 in the 
Biopharmaceutics Classification System (BCS) since SEDDS can improve their solubility by 
dissolving them in the oil phase and preventing precipitation in the GI tract [93]. The choice of 
oil phase is mainly based on the solubility of the lipophilic agent in it. The selected oil should 
improve the loading capacity and sustain the release profile to avoid drug precipitation.  Indeed, 
SEDSS can eliminate the factors that reduce the bioavailability of BCS4 represented by low 
solubilisation, enzymatic degradation, gut wall efflux and low permeability [96].  Besides 
improving the solubilisation of BCS4 drugs, SEDD systems are characterised by high 
concentrations of surfactants/co-surfactants which can reversibly disrupt intestinal epithelial 
membrane and enhance the intestinal permeability of these agents [97]. SEDDS can also inhibit 
the gut wall efflux through the inhibition of P-glycoprotein (P-gp) [98]. I.e., P-gp is a 
transporter protein served as efflux pump so substrate of these transporters will permeate higher 
if P-gp is inhibited. 
The inhibitory mechanism is related to certain types of surfactants used in SEDDS which can 
influence the efflux role of P-gp through modifying the structure of lipids within the epithelial 
membrane [99]. Surfactants like PEG based surfactants, TPGS (d-Alpha-Tocopheryl 
Poly(ethylene glycol), polysorbate 80 [100], polyoxyethylene 40 stearate (Myrj® 52) [101] 
and cremophor EL [102] were reported to inhibit P-gp efflux and improve the bioavailability 
of P-gp substrate agents. In addition to the effect on P-gp, surfactants like Polysorbate 80, 
TPGS, sucrose laurate, Cremophor RH 40 and Cremophor EL (PEG-40 and PEG-35 
hydrogenated castor oil) can supress the enzymatic activity of cytochrome P450 3A4-mediated  
and hence it can influence the pharmacokinetics of these enzymes substrate agents [103].  
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SEDDS containing Cremophor RH40 or Tween 80 have shown inhibitory effect on cytochrome 
P450 3A in murine hepatocytes model [104].      
Beside the main use of SEDDS for the delivery of hydrophobic agents, recently, this system 
was explored as a carrier for orally administered hydrophilic macromolecules which are prone 
to intestinal enzymatic degradation. To be loaded into the oil phase, these hydrophilic agents 
are turned into hydrophobic agents through a technique known as the Hydrophobic Ionic Paring 
technique (HIP) [105]. This HIP technique includes the pairing of peptides with a 
macromolecular hydrophobic counter ion which turns the peptides into hydrophobic agents 
with high oil solubility. Designing this technology enables the loading of peptide/proteins into 
SEDDS to provide a high protection against enzymatic degradation.  
4.2 SEDDS as a Muco-Diffusive System: Role of Glycols at the Surface of Oil Droplets 
Originally, the main purpose of employing SEDDS for oral delivery of hydrophobic agents is 
to boost their bioavailabilities by improving both their solubility and loading capacity [106]. 
In other words, the mucus barrier is not the limiting step for the permeation of hydrophobic 
agents. SEDDS has not been utilized to enhance the diffusion of lipophilic agents across the 
intestinal mucosal barrier. Therefore, studying the diffusion of a lipophilic drug loaded into 
SEDDS through the mucus barrier has rarely been reported. For example, Sunazuka et al. used 
SEDDS to load a class 2 agent (Fenofibrate) then studied the permeation of the system through 
the mucus barrier consisting of 3% (w/w) porcine gastric mucin layer using the Transwell 
Membrane technique [107]. This study showed that SEDDS containing a surfactant with a 
lower M.wt PEG NIKKOL HCO-40 (PEG-40 hydrogenated castor oil) exhibited higher mucus 
permeation compared to the system containing PEG with higher M.wt NIKKOL HCO-60 
(PEG-60 hydrogenated castor oil).  
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The mucus barrier and mucosal enzymes are the main reasons that limit the oral delivery of 
peptides [108]. Hence, more recently, utilising of SEDDS as a nano-carrier to improve their 
mucus permeation has been extensively studied. There are a number of reasons for this. Firstly, 
SEDDS can provide effective protection against enzymatic degradation due to their efficient 
encapsulation and sustained release capability which renders a free peptide unavailable which 
in turn extremely minimise their hydrolysis by the enzymatic activity in the intestine [109,110]. 
The HIP technique, as was described above, has been used as the main pathway to improve 
loading of peptides into SEDDS systems. The HIP of peptides was widely studied to explore 
the best pathways to improve the loading of peptides into SEDD systems. For example, 
Griesser et al. investigated a variety of ion pairing surfactants and their complexation efficiency 
with different peptides like leuprorelin, insulin and desmopressin [111]. Sodium docusate 
emerged as the most efficient ion paring agent irrespective of the peptides, which translated 
into efficient loading capacity into a SEDDS model. The second reason to make SEDDS an 
excellent nano-carrier of peptide through intestinal mucus barrier is the high content of 
surfactants within the SEDDS which can highly reduce the intestinal enzymatic activity against 
loaded peptides [112].  
However, high permeation across the intestinal mucosal barrier is the main reason to utilise 
SEDDS as a nano-carrier for peptides mucus delivery. SEDDS can improve the mucus 
permeation of macromolecular peptides due to the flexible nature of the fluidic droplet and the 
high hydrophilic nature of the droplets’ surface [113]. Interestingly, most of the published work 
on SEDDS with high diffusivity across intestinal mucus barrier exhibited a mutual factor. This 
factor is the presence of a glycol moiety within the surfactants/co-surfactants compositions of 
the SEDDS. The mucus-diffusive SEDDS that is reported in the literature is mainly composed 
of surfactant/co-surfactant of polyglycol derivatives of glycerides. Thus, it seems that these 
glycol moieties at the surface of oil droplets form a muco-inert hydrophilic surface that avoids 
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the interaction of oil droplets with mucus components in a similar mechanism of PEGylated 
solid NPs and PEGylated liposomes.  
For this reason, the majority of the published work on the improvement of mucus permeation 
of peptides employing SEDDS involve use of the HIP technique, with loading of the ion paired 
lipophilic peptide into a SEDDS with glycol moiety at the surface. For example, Zupančič et 
al. demonstrated that complexation of daptomycin peptide with a dodecylamine hydrochloride 
improved its lipophilicity and loading capacity into the SEDDS system comprising an oil phase 
consisting of Dermofeel MCT (Glycerol tricaprylate) and Capmul MCM EP (glyceryl 
monocaprylate) and PEG based nonionic surfactants consisting of Cremophor RH40 and 
Cremophor EL [114]. This SEDD system improved the permeation of daptomycin twofold 
through pig intestinal mucus. The same researcher demonstrated a similar advantage of HIP 
and loading into SEDDS on the oral delivery of enoxaparin peptide. Incorporation of this 
peptide into a SEDDS with medium chain length lipids in which the surfactant mixture is 
compsed of 30% Cremophor EL (PEG ethers of hydrogenated castor oil) and 10% propylene 
glycol improved the mucus permeation twofold and improved its oral bioavailability [115].  
Hintzen et al. also reported the protective effect of incorporating leuprolide (ion paired with 
sodium oleate) into a SMEDDS system composed of Capmul MCM and captex 355 as oils and 
a surfactant mixture of Cremophor EL (PEG ethers) and 10% propylene glycol [116]. The 
enzymatic degradation in a trypsin solution of leuprolide oleate loaded into the SEDDS was 
compared with a loading of the free leuprolide acetate and the leuprolide acetate.  Figure 3 
shows that SEDDS significantly enhanced the stability of leuprolide oleate against the 
enzymatic degradation while both free leuprolide acetate and leuprolide acetate loaded into 
SEDDS expressed a fast degradation. In vivo studies showed an improved oral bioavailability 
of leuprorelin in rat models.  
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SEDDS is one of the widely exploited nano-systems to  enhance the bioavailability and mucus 
diffusivity of insulin [117]. Karamanidou et al. explored the hydrophobic ion pairing of insulin 
with dimyristoyl phosphatidylglycerol to improve its hydrophobicity and loading capacity into 
an SEDDS containing a derivative of PEG emulsifier (Cremophor EL) [118]. The stability of 
insulin in a solution of common intestinal enzymes was highly improved indicated efficient 
shielding by the system and up to 40% permeation after six hours across purified porcine 
intestinal mucus in transwell inserts. 
 
Fig.3. Degradation profile in a trypsin solution of free leuprolide acetate (0), leuprolide acetate 
loaded into SEDDS (Δ) and leuprolide oleate loaded into SEDDS. Values are expressed as 
mean ± SD (n= 3). Adopted from Hintzen et al. [116].  
The intestinal mucus permeation of another peptide used for diabetes mellitus treatment 
(exenatide) was studied from SEDDS, prepared using Cremophor EL (PEG) as surfactant and 
Propylene glycol as cosolvent. Hydrophobic ion pairing of exenatide with sodium docusate 
improved the hydrophobicity of the peptide (logP 2.1) and the loading capacity [119]. Mucus 
permeation of exenatide loaded into SEDDS was enhanced by 2.7 times and oral bioavailability 
of 14.62 % was achieved compared to the subcutaneous application. The SEDDS system was 
reported to improve the intestinal mucus permeation of another peptidic drug (octreotide) 
where this peptide was ion paired and loaded into a SEDDS comprising BrijO10, 
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octyldodecanol, propylene glycol and ethanol [113]. This SEDD system showed a very high 
diffusion coefficient through pig intestinal mucus, high stability against intestinal lipase 
enzymes and significant increase in bioavailability. The same group showed the same outcome 
of improving the mucus permeation of desmopressin peptide by using SEDDS with glycol 
surfactants [120].    
Ijaz et al. [121] employed a SEDDS strategy to protect a model peptide (lanreotide) which is 
susceptible to sulphide-thiol exchange owing to a disulphide linkage present in its molecule. 
These disulphide groups can interact with the intrinsic reduced glutathione (GSH) and reduce 
them into thiols and thus degrade the peptides. Lanreotide was efficiently paired with sodium 
deoxycholate then incorporated within a system composed of Capmul MCM (oil) and a 
surfactant mixture of Kolliphor EL(PEG-35 hydrogenated castor oil) and Migylol 840 
(Propylene Glycol Dicaprylocaprate). The formulation exhibited a significant protection 
against GSH and enriched casein peptone within the first three hours with 50% of lanreotide 
remaining intact. A similar protection against Glutathione was reported for Desmopressin 
where an ion paired with Sodium docusate was loaded onto a SEDDS composed of Capmul 
907 P (Propylene Glycol Heptanoate) as oil and Cremphor RH40 and Transcutol (Diethylene 
glycol monoethyl ether) as surfactants[122]. 
4.3 Other Strategies to Improve Mucus Permeation of SEDDS: Mucolytic SEDDS 
unhealthy mucus in CF and other pathological conditions is characterised by atypical viscosity 
and water content where mucolytic agents can be highly effective to eliminate the entrapment 
efficiency of mucus [123]. A rational approach to achieve better muco-penetration can involve 
localised micro-mucolysis around the droplets  to weaken mucus viscosity and thus improve 
droplets permeation  [73,77]. The aim is to load the SEDDS with a mucolytic agent with the 
ability to slowly release the agent during the transit of droplets through the mucus in order to 
reduce the mucus resistance to the moving droplets without inducing a massive destruction to 
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the whole mucus barrier. This strategy has shown a great improvement in the mucus permeation 
of SEDDS. Leichner et al. investigated the potential of a mucolytic protease enzyme (Papain 
ion paired with Sodium deoxycholate by HIP) to disrupt intestinal mucus barrier [124]. In this 
study, SEDDS system loaded with papain- deoxycholate exhibited up to twofold higher 
diffusion across intestinal mucus barrier compared with the unloaded SEDDS.  
A more exhaustive study to understand the effect of mucolytic agents like bromelain, papain 
and trypsin was conducted by Efiana et al. [125]. The enzymes were ion paired with a 
hydrophobic surfactant (palmitoyl chloride) with a maximum conjugation of up to 47.8% for 
papain compared with other peptides.  Mucus permeation of papain-Palmitate loaded into a 
SEDDS with a derivative of PEG surfactant was found to be around 5 times higher than 
unloaded SEDDS when measured using the Transwell Method. In another study, Rohrer et al. 
exploited the capacity of thiol groups to break the disulfide linkages of the mucus network 
using  two novel thiomers, thio butyl amidine dodecyl amine (TBA-D) and 2-mercapto-N-
octylacetamide (TGA-O) [126]. The incorporation of TBA-D and TGA-O incorporated into a 
SEDDS formulation (propylene glycol 10%) resulted in a reduction of the dynamic viscosity.  
Multiple Particle Tracking (MPT) studies on these systems diffusion revealed a high difference 
in the diffusion of the SEDDS loaded with TBA-D (66 folds) compared with thiol free SEDDS. 
 
 
 
4.4 Other Strategies to Partially Improve Mucus Permeation of SEDDS 
4.4.1 Zeta Potential Inverting SEDDS 
The surface charge of oil droplets is an important parameter that can affect the diffusivity of 
the SEDDS in a similar manner to solid NPs [68]. The surface of an oil droplet should be 
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neutral or slightly negatively charged to avoid any electrostatic or ionic interaction with the 
mucus components having sialic and sulfonic acid residues [127]. However, a negatively 
charged droplet would be significantly impeded for endocytosis mediated absorption at the 
intestinal epithelial interface [128]. The mutually opposite requirement of surface charge at the 
two subsequent interfaces can be achieved using a system capable of reversing its zeta potential 
in response to certain variables at these interfaces and thereby achieve efficient mucus 
permeation as well as cellular absorption.  
Suchaoin et al. demonstrated that when formulating a SEDDS containing 1,2-dipalmitoyl-sn-
glycero-3-phosphatidic acid sodium (PA), it formed a negatively charged system which 
favoured efficient mucus permeation. However, because this PA is a synthetic substrate of 
intestinal alkaline phosphatase enzyme (IAP), rapid cleavage of anionic phosphates from PA 
took place when the SEDDS reached the intestinal epithelia, where IAP are overexpressed. 
This inverted the overall surface charge of SEDDS from -ve to +ve providing improved 
permeability across the intestinal epithelial membrane. The enzymatic cleavage and subsequent 
release of anionic phosphate groups was ascertained using caco-2 monolayer in vitro studies 
expressing IAPs and using male SD rat intestine fixed in an Ussing-type chamber (ex vivo). In 
both cases, the released phosphate was measured using malachite green assay. The in vitro 
studies showed a 12.3% release of the total phosphate, the ex vivo experiment (rat intestine) 
suggested a fast release of  23.1% [129]. Further work reported by Griesser showed that 
SEDDS, comprising phosphorylated polysaccharides (hydroxypropyl starch phosphate and 
maize starch phosphate), achieved higher mucus permeation as compared to control groups due 
to the net negative charge provided by the phosphate groups [130].  Subsequently, these 
phosphate groups were cleaved down by IAP at the intestinal epithelia which inverted the 
surface charge from negative to positive and thus could facilitate intestinal absorption in vivo. 
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Recently, a conjugate of phosphorylated tyrosine with octadecylamine was reported to be a 
flip-flop agent possessing both negative and positive charge groups within the same molecule 
[131]. This agent when incorporated into a SEDDS would initially impose a negative charge 
on the surface due to phosphate groups and provide efficient mucus permeation of the 
nanodroplets. The surface charge would alter significantly after exposure to IAP and 
subsequent cleavage of phosphate groups would leave the amine groups to populate onto the 
surface and provide a positive charge to the nano-droplets which in turn would cause intestinal 
absorption and inhibit back diffusion.  
4.4.2 Supersaturated SEDDS  
The use of considerably large amounts of surfactants in these systems pose the danger of GI 
side effects [132,133]. A novel class of SEDDS has recently emerged where SEDDS is 
composed of lower concentrations of surfactants and a precipitation inhibitor to achieve a 
supersaturated state of a drug in the intestinal fluid. This strategy can be achieved by utilizing 
a hydrophilic polymeric system along with the surfactants which will inhibit the crystallization 
of the loaded drug. Thus this strategy enables the poorly water soluble drugs to reach their 
supersaturated state within the SEDDS and still not-precipitated [134]. 
In a study reported by Lee et al. Soluplus® (derivative of polyethylene glycol graft copolymer) 
was employed to prevent precipitation due to high drugs concentration and thus forming a 
supersaturated SEDDS for the delivery of dutasteride [135]. The system achieved a 1.3-fold 
higher bioavailability for dutasteride in rats in comparison with pristine SEDDS and a 2-fold 
improvement in maximum plasma drug concentrations.  
Thomas et al. developed a supersaturated SEDDS system through freeze-thawing approach to 
stabilise Simvastatin (a poorly water-soluble drug) at supersaturating concentrations. In vivo 
studies showed significant improvements in oral bioavailability and terminal half-life 
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compared with the control SEDDS [136]. Similarly, oral bioavailability of Silybin was found 
to be improved as much as 3-fold compared to conventional SEDDS when HPMC (Hydroxy 
Propyl Methyl Cellulose) was employed as a precipitation inhibitor in a SEDD system 
composed of SLB, Labrafac CC (Capric Triglyceride), Cremophor RH40, Labrasol 
(Caprylocaproyl Polyoxyl-8 glycerides) [137].   
5. Techniques to Assess the Diffusion of SEDDS through the Mucus Barrier 
The quantification of diffusion of NPs or SEDDS through mucus barrier posed great difficulties 
to researchers [138]. Mucus barrier properties can be highly affected during the experiment, 
for example, atmospheric factors can increase the humidity or dryness of mucus sample in the 
in vitro testing which in turn can affect the diffusion data of particles/droplets through mucus 
[139]. Designing of the In vitro test should be carried carefully to avoid equivocal results 
leading to misjudgement of the diffusivity of particles/droplets through the mucus laden barrier. 
This review will describe only the techniques that have been reported in previous work to 
quantify the permeability of SEDDS in mucus. Other sophisticated techniques like Pulsed-
Gradient Spin-Echo NMR (PGSE-NMR) [140] that widely utilized to quantify the diffusion of 
NPs in mucus but not for SEDDS will not be reported in this review. Similarly, less frequently 
used techniques with SEDDS like Small Angle Neutron Spectroscopy (SANS) will not be 
described in this review  [141] 
5.1 Transwell Chamber Techniques 
The method is considered to be the most frequently utilized technique to measure the 
permeation of SEDDS across a static layer of mucus. The technique is essentially composed of 
a parallel or vertical arrangement of donor and acceptor chambers which are separated through 
a mucus barrier loaded between two layers of membranes. The quantification of permeated 
SEDDS is associated with the quantity of drug in the receptor media indicating the crossing of 
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drug and SEDDS through the mucus barrier. The receptor compartment is filled  with a suitable 
buffer in which the drug/dye is highly soluble [142,143].  
This technique is simple, cost effective and flexible in terms of changing the parameters during 
the experiments. For example, with this technique, it is possible to use a small receptor 
compartment which enables testing the permeation at low drug doses. Also the Transwell 
Chamber Technique allows to change the mucus constituents throughout the course of the 
experiment to resemble some pathological circumstances [144]. In this regard, Boegh et al. 
(2015) utilised alternative method in which caco-2 cells were grown first then porcine intestinal 
mucus was added to form mucosal layer inserted between the two vertical compartments 
[3,145]. This technique, however, measures the bulk permeation only of the loaded drug/dye 
but it does not measure the behavioural movement of individual particles/droplets in the mucus 
[144]. Also, this method takes considerably long time to allow drug movement through the 
layer of mucus. This delay might suffice the chances of mucus enzymatic degradation or 
diluting the mucus sample which in turn cause leaking of mucus into receptor chamber [146].  
The method has been widely used to test the mucus permeation of SEEDS. Friedl et al. set a 
Transwell Technique to study the factors affecting the permeation of SEDDS through a pig 
intestinal mucus layer where the crude mucus was centrifuged at high speed to yield a robust 
packed mucus layer [147]. The study showed that SEDDS with smaller particle size (12 nm) 
expressed about nine times higher diffusion than the SEDDS with particle sizes of 455 nm. 
Accordingly, Zupančič et al. assessed the permeation of a peptide (daptomycin ion-paired with 
dodecylamine hydrochloride) loaded into an SEDDS versus the free permeation of the SEDDS 
that dissolved in buffer and was added into the receptor compartment [114]. In this study, 
Transwell inserts having a pore size of 3 micron were employed to minimise the membrane 
effect and 50 mg of mucus was added onto the membrane to form a layer of 100–150 μm 
thickness to mimic the mucus intestinal barrier. The study suggested that the permeation of 
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daptomycin loaded into the SEDDS was significantly higher than that of free daptomycin 
(Figure 4).   
Mucus diffusion of Desmopressin-docusate loaded into a variety of SEDDS formulations (with 
varying particle size and zeta potential) was determined utilizing a Transwell Method 
analogous to Friedl et al. [58]. The comparison was also conducted with other nano-carriers 
including liposomes and Polyacrylic acid-based NP as reference. The Transwell studies 
indicated an unequivocal improvement in the mucus permeation capabilities of SEDDS as 
compared to reference nano-carriers. This study also showed that SEDDS with a smaller 
particle size (25 nm) and most negatively charged  (zeta potential -25 mV) is the most effective 
muco-diffusive compared with other SEDDS [58]. The Transwell method was utilized to 
understand the influence of papain on the mucus diffusion of a SEDDS  [124]; to understand 
the mucus penetration profiles of phosphorylated zeta potential changing SEDDS [130]; and 
for the determination of the permeation potential of curcumin loaded into SEDDS [148].  
 
Fig. 4. Free daptomycin diffusion in phosphate buffer pH 6.8 (as white bars) compared to the 
diffusion of daptomycin loaded into SEDDS (black bars) through the pig intestinal mucus 
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barrier utilizing Transwell technique.  All data are reported as mean ± SD (n= 3). Adopted from 
Zupančič et al. [114]. 
5.2 Rotating Silicone Tube 
This technique is similar to other traditional techniques where it involves the measurement of 
the bulk movement of particles, dyes or drugs in a mucus sample confined in a tube [56]. The 
process is simple; mucus is added to a tube (usually silicon based tubing) being closed from 
one end with a cap. The length of the tube can be up to 5 cm and the diameter up to 0.4 cm.  
Then SEDDS (loaded with a dye or drug) is added through the open end, which is then locked 
using a separate cap and the tube is kept rotating horizontally at 37 °C for a predetermined time 
(8-24 hours) [149]. The tubes, after that, are frozen at -80 °C for about 1 hour and then cut into 
2 mm pieces starting from the end where particles were added and finally the quantity of 
drug/dye is measured within each piece.  
The technique enables measurement of how deep particles can diffuse through a mucus sample 
and also quantifies the permeation of these particles which can be described in relation to the 
rate of diffusion of the tested SEDDS. Moreover, this cost-effective technique enables variation 
of the content of mucus within the tube where mucus with different properties can be filled 
within each tube segment [150]. However, the quantification process involved reflects the 
amount of loaded drug/dye that is diffused through the mucus and not the quantity of the 
SEDDS where the loaded cargo can be released in the mucus during the time of experiment. 
The Bernkop-Schnürch group have widely the rotating silicone tube method to assess SEDDS 
permeation in mucus. For example, Suchaoin et al. tested the diffusion of a zeta potential 
changing SEDDS loaded with Lumogen red through a pig intestinal mucus sample using the 
rotary tube technique where the crude mucus was washed with 0.1 M sodium chloride then 
centrifuged at 9000 rpm prior to the experiment [129]. Quantifying the Lumogen red in 
subsequent segments of the tube enabled the study of the effect of shifting the surface charge 
on the diffusion of the SEDDS. Negatively charged SEDDS permeated efficiently at the early 
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stage of the experiment whereas, within time, converting the SEDDS into a positively charged 
system led to trapping in the mucus.   
Zupancˇicˇ et al. utilized this technique to study the permeability of SEDDS loaded with 
Fluorescein diacetate (FDA) in a system formulated with varied chain length lipids (long to 
small chain lipid versus no lipid). The study showed the diffusion of SEDDS with no lipids 
was higher than the diffusion of other tested systems [151]. Similarly, the same group used the 
rotary tube technique to understand the influence of different mucolytic agents on the relative 
movement of a SEDDS consisting of Captex 355 (Capric Triglyceride), Kolliphor EL and 
propylene glycol [152]. This study showed that the SEDDS loaded with papain had a higher 
diffusion through mucus compared with the same system loaded with other mucolytic agents.   
  
5.3 Fluorescence Recovery after Photo-Bleaching (FRAP)    
FRAP is a broadly employed technique to quantify the bulk movement of fluorescently labelled 
particles/droplets in mucus and any viscous solution or hydrogel biopolymer [153].  
This technique involves inoculation of a SEDDS loaded with fluorescent dye into the 
biopolymer sample on a microscopic slide sealed with a coverslip and placed under 
fluorescence microscopy. The sample is left for 15 minutes for equilibration then a confined 
zone of the mucus sample is exposed to a high intensity laser beam for few seconds resulting 
in bleaching of the fluorescently tagged droplets. The fresh (unbleached) fluorescent droplets 
tend to relocate to already bleached section within the biopolymer sample leading to regain the 
strength of the fluorescence signal at that section. The bulk diffusion is calculated based on the 
time difference between the loss and regaining of fluorescent signal [154].  
In the last decade, this technique was used to measure the diffusion of viruses and peptides. 
For examples, the bulk diffusions of a huge number of different sizes fluorescent peptides as 
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well as viruses were quantified by FRAP to understand the effect size and surface properties 
on their diffusions in mucus [61]. Saltzman et al. [155] utilised this method to understand the 
factors affecting the movement of antibodies in cervical mucus. Accordingly, Afdhal 
[156]expanded the use of FRAP to study the effect of mucin concentration on the tendency of 
cholesterol particles to aggregate where it was observed that the size of cholesterol vesicles 
would be influenced by the relative interaction with mucin resulting in aggregation of vesicles 
into larger particle sizes. More importantly, in accordance with SEDDS, FRAP was used to 
measure the diffusion of oil nano-droplets through mucin solution which showed no effect of 
the droplet size compared to a significant impact of the size of the lipid phase (medium or long 
chain lipid) on the bulk diffusion of SEDDS [157].  
 
5.4 Multiple Particle Tracking Technique 
MPT is a microscopy based technique pioneered by Hanes group to examine the motion of 
fluorescent particles in soft materials as a function of time [158]. The same group developed 
this technique to study the diffusion of fluorescent nano-systems across biological fluid and 
mainly through the mucus barrier [159]. This technique enables researchers to quantify the 
diffusivity of each individual particles at nanoscale level across a biopolymer system  like 
mucus [160] and also understanding the structural and micro-rheological properties of that 
biopolymer system [161]. While most in vitro techniques provide the measurement of the bulk 
diffusion of particles, droplets or loaded drugs through mucus [66], MPT can simultaneously 
visualize, track and detect the individual diffusion coefficients of hundreds fluorescently 
labeled particles in a mucus samples [162]. 
MPT technique includes the use of either epifluorescence or confocal microscopy supplied with 
a high speed camera to record videos for the movements of fluorescently labelled 
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particles/droplets in mucus [163]. These movements are ordinarily captured in X-Y dimensions 
within a single plane in the Z direction since mucus is an isotropic system and movements are 
equal in X, Y and Z dimensions [144]. Auto-fluorescence from mucus should be considered 
before the selection of fluorescent dye for particles’ labelling since it can interfere with tracking 
[164]. Another factor that needs to be considered is the efficiency of dye loading into the 
particles/droplets where these loaded dyes should not be heavily leaked outside the particles 
before/during the experiment to avoid background noise. In this regard, SEDDS should be a 
very suitable system for the MPT analysis since such systems with an oil core allows the 
efficient incorporation of lipophilic fluorescent dyes that provides robust MPT studies in mucus 
[165]. Table 1 shows some of the published work in which SEDDS were efficiently labelled 
with fluorescent dyes and the method used to analyse the in vitro diffusion of SEDDS through 
mucus. 
Table 1: Compositions of SEDD systems which are efficiently labelled with fluorescent dyes for 
in vitro testing of droplets permeation through mucus barrier.   
composition Dye employed Technique Reference 
Brij™O10 as surfactant 
and octyldodecanol and 
paraffin as oil 
Lumogen red 
 
Multiple particle tracking 
[113] 
 Fluorescence labelled  
Dextran 
Ex vivo permeation 
Capmul MCM (30%), 
Captex 355(30%), 
Cremophor EL (30%) and 
propylene glycol (10%). 
Lumogen red 
 
 
Multiple particle tracking 
[166] 
fluorescein diacetate 
(FDA) 
Rotating tube method 
Different combinations of 
oil including Capmul 
MCM EP and oleic acid. 
Different combination of 
surfactants including 
Capmul PG8, and 
Cremophor EL. 
Lumogen red Single particle tracking 
[167] 
Pluronic F-127 coated 
liposomes 
Coumarin 6 CLSM studies on 
intestinal segments [86] 
Ethyl oleate and Captex as 
oil with different 
combinations of 
Cremophor, transcutol and 
triacetin as surfactants 
Fluorescien diacetate Standardized Transwell 
diffusion plates 
[168] 
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Video recording is followed by post-acquisition analysis using tracking software such as 
ImageJ to simultaneously track the movements of each individual droplet and to convert these 
movements into trajectories of hundreds of individual droplets [169]. These trajectories are 
firstly expressed in pixels then converted into the metric system based on the setting of 
microscopy, i.e., the trajectories are converted into metric distance to calculate the 
displacements of each particle. The 2-dimentional displacements of any droplets at certain time 
intervals are calculated as the mean squared displacement (MSD) per time interval MSD(n) = 
(XΔt)2 + (YΔt)2). For each SEDDS species, the MSD of hundreds of particles are calculated then 
the geometric mean of these MSDs is calculated to represent the ensemble MSD <MSD> of 
that particulate species. Ensemble diffusion coefficient <Deff> of any particle species at certain 
time interval is calculated by dividing the <MSD> by the frame rate multiplied by 4 since 4 
represented the 2 dimentional displacement in X-Y direction and the frame rate is the time 
scale at which MSD was calculated  [65].  
MPT technique can reveal not only the diffusion of droplets in the mucus but the behavioral 
movements of these droplets. Figure 5A shows the trajectories of oil droplets (SEDDS) in 
mucus samples where some droplets appeared trapped by the mucus and some appeared 
diffusive with pearl on string behavioral movement through the mucus (image captured by 
Gumbleton group) [170]. Figure 5B represents the measurement of <MSD> through 
transferring the trajectories into metric displacements in X-Y dimensions then calculating 
<MSD>. Figure 5C clarifies the different modes of behavioural movements of particles in 
which pearl on string movement is associated with the consecutive binding and unbinding of 
certain particles to the mucin. Random movement suggests the lack of interaction between a 
particle and its environment and immobilised movement is related to a totally trapped particle. 
In other words, these modes of particles’ movements in the mucus actually reflect the 
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mechanism of particles’ interactions with mucus components [171]. These particles-mucus 
interactions can be further analysed to give a clear description of the structural, mechanical and 
micro-rheological properties of the mucus samples [172].     
MPT was recently utilized to quantify the diffusion of two discrete SEDDS formulations across 
freshly excised pig intestinal mucus. In the first MPT study, the mucolytic effect of thiomer 
loaded into SEDDS was revealed where the SEDDS system loaded with thiol exhibited a 
significantly higher diffusion coefficient compared to the thiol-free SEDDS [173].  
Accordingly, MPT study on the diffusion coefficient of SEDDS showed an inverse relation 
between the ratio of the oil phase (octyldodecanol) and the diffusion of the system indicating 
the impact of the lipophilic interaction between the oil phase and the lipophilic components of 
the mucus [174].  
 
Fig. 5. Tracking of SEDDS oil droplets by the MPT technique using Fiji Image J 
software (Gumbleton group) [170]. (A) Trajectories of different oil droplets; (B) 
Transferring on trajectories into metric movement to measure   the <MSD> and <Deff> 
of particles; (C) Modes of particles movements within mucus sample.  
 
6. Conclusion  
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SEDDS has shown high tendency to be an effective system for delivery of drug payloads across 
the mucosa. Literature review showed SEDDS can improve the diffusion of both hydrophilic 
macromolecule and lipophilic agents across intestinal mucus barrier. In terms of clinical unmet 
conditions, SEDDS has been extensively used to improve the permeation of loaded drugs, 
especially agents prone to enzymatic destruction such as peptides. The majority of these SEDD 
systems which showed high diffusivity across the mucus barrier have one factor in common, 
which is the presence of PEG derivatives as a co-surfactant. These glycol moieties seem to 
increase the flexibility of the surface of oil droplets and to diminish any lipophilic bonding 
between these oil droplets and mucus. In summary, utilizing SEDDS for mucus delivery has 
the following advantages: (i) high protection of loaded drugs against enzymatic environment; 
(ii) high permeation through mucus barrier; (iii) high loading capacity; and (iv) ease of 
preparation compared with solid nano-carriers. 
However, even with the promising findings from SEDDS, There have been far fewer studies 
carried out on mucus diffusion of SEDDS than for the solid nano-systems. This has led to many 
gaps in knowledge, for example, on how surfactant and co-surfactant properties can change the 
diffusion of SEDDS through the intestinal mucus barrier. . I.e., the published work on how 
surfactants and co-surfactants can improve mucus permeation of SEDDS is limited on the use 
of PEG-surfactants derivatives like PEG-35 and PEG-40 Hydrogenated Castor Oil to form a 
slippery-surface oil droplet that can permeate through mucus barrier. This limitation also 
applies to the impact of the oil phase where only few studies have been conducted to clarify 
the influence of the M.wt, size or chain length of the oil/lipid phase on the diffusion of the 
system.  
Moreover, the work on promising SEDD systems like the zeta-changing system is still 
inadequate with few publications in the last decade. This is similar to the industrial approach 
where only limited work has been reported even though Sandimmune®, the first SEDDS 
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product was released to the market two decades ago [175]. Therefore, it can be concluded that 
SEDDS has high capacity to deliver different hydrophilic/lipophilic agents across the intestinal 
mucus barrier but further studies are required to have a better understanding on the factors 
affecting the mucus diffusion of this system.  
7. Progress towards Clinical Translation 
A lot of promise has been put forth by the in vitro success of the mucus permeating SEDDS 
which is imperative to be translated to patient bedside through exhaustive preclinical and 
clinical evaluation. Robustness in results in terms of safety, efficacy as well as improvement 
in the pharmacokinetic performance of candidate drugs is necessary for regulatory approval. 
There have been a scarce but positive precedence of the in vivo pharmacokinetic performance 
of mucus permeating SEDDS where significant improvement in oral bioavailability of 
hydrophilic macromolecules through HIP was reported as discussed above [113,115,116,119]. 
There are, however, concerns regarding the in vitro-in vivo correlation of SEDDS formulations 
along with challenges pertaining to stability and manufacturing cost towards the clinical 
translation of the evident advantages of SEDDS [18]. Another criticism associated with 
SEDDS is the unpredictable impact of surfactants on the membrane permeability [176]. 
Notwithstanding the mentioned criticism, SEDDS have found its way into the clinic as a carrier 
formulation for oral delivery of hydrophobic agents like cyclosporine (Neoral) [177], ritonavir 
(Norvir)[178], fenofibrate (Lipirex) [179] to mention a few. The potential of SEDDS for 
improvement of oral absorption of low permeable drugs have been already established and thus 
must be the carrier of choice of such agents. However, the correlation of the in vitro outcomes 
such as mucus permeation and controlled release with actual improvement of bioavailability in 
preclinical as well clinical setting is necessary for the eventual translation of the technology to 
the commercial products [18]. Further exploration of the quantitative technologies for mucus 
permeation is necessary to expedite the development of the SEDDS based delivery of 
31 
 
hydrophilic macromolecules and hydrophobic agents across intestinal mucus barrier 
efficiently. 
  8. Future perspectives 
SEDDS is an effective strategy to augment the mucus permeation and enhanced oral 
bioavailability of hydrophilic peptides/proteins and lipophilic agents. However, the industrial 
utilisation of SEDDS for mucus delivery is still constrained and requires comprehensive 
exploration of various aspects and variables to reach the clinic. As is evident from the 
discussions above, an improvement in the molecular understanding of surfactant/co-surfactant 
and oil behaviours can be a potential breakthrough in designing SEDDS with enhanced 
efficiency and in vivo formulation stability which is imperative for clinical translation.  
An important aspect which requires attention from the community is the incorporation of 
stimuli triggers within the SEDDS to pass the various physiological roadblocks present within 
the path of the mucus barrier. Zeta potential reversing systems exemplify theses innovative 
stimuli triggers which enable SEDDS to cross mucus barriers into intestinal epithelial 
absorption sites. In this regard, it can clearly be seen that there is a requisite to execute more 
studies to determine the fate of SEDDS as a system across the mucus and on the intestinal 
epithelia. The innovative techniques discussed provide a promising repertoire for precise 
analysis of SEDDS within the lumen and consequently into the target tissue. However, the 
selection of the technique which can precisely provide the vital evidence regarding mucus 
permeation is also a concern considering the cost and time constraints associated with certain 
techniques. MPT appears to be the right technique to comprehensively explain the parameters 
affecting mucus permeation of these systems. 
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